The dose figures here trace back to published chronic hepatitis B trials rather than a US prescribing label, because thymosin alpha-1 is not FDA-approved in the United States. Those trials commonly used 1.6 mg given subcutaneously twice weekly, typically for around 26 weeks.[1]
Reviewed for accuracy · Last reviewed July 8, 2026The most commonly studied clinical regimen in chronic hepatitis B trials is a fixed subcutaneous dose given twice weekly, typically for about 26 weeks:
Treat this as a description of the studied clinical regimen, not a recommendation for research use. Approval status, indications, and dosing vary by country, and the underlying trial base for hepatitis B is small, so the numbers should be read cautiously.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.